Dasatinib
Information
- Drug Name
- Dasatinib
- Description
- Entry(CIViC)
- 109
CIViC
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| The use of nilotinib and dasatinib, second-generat... | ABL1 | ABL1 BCR-ABL | Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3-p210BCR-ABL1 cell li... | ABL1 |
ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In 3T3 fibroblasts expressing the G253C mutation h... | DDR2 |
DDR2 p.Gly253Cys (p.G253C) ( ENST00000367921.8, ENST00000446985.6, ENST00000367922.7 ) DDR2 p.Gly253Cys (p.G253C) ( ENST00000367921.8, ENST00000367922.7, ENST00000446985.6 ) |
Sensitivity | true | CIViC Evidence | detail |
| In 3T3 fibroblasts expressing the G505S mutation h... | DDR2 |
DDR2 p.Gly505Ser (p.G505S) ( ENST00000367921.8, ENST00000367922.7, ENST00000446985.6 ) DDR2 p.Gly505Ser (p.G505S) ( ENST00000367921.8, ENST00000367922.7, ENST00000446985.6 ) |
Sensitivity | true | CIViC Evidence | detail |
| In 3T3 fibroblasts expressing the G774V mutation h... | DDR2 |
DDR2 p.Gly774Val (p.G774V) ( ENST00000367921.8, ENST00000367922.7, ENST00000446985.6 ) DDR2 p.Gly774Val (p.G774V) ( ENST00000367921.8, ENST00000367922.7, ENST00000446985.6 ) |
Sensitivity | true | CIViC Evidence | detail |
| In 3T3 fibroblasts expressing the I638F mutation h... | DDR2 |
DDR2 p.Ile638Phe (p.I638F) ( ENST00000446985.6, ENST00000367921.8, ENST00000367922.7 ) DDR2 p.Ile638Phe (p.I638F) ( ENST00000367921.8, ENST00000367922.7, ENST00000446985.6 ) |
Sensitivity | true | CIViC Evidence | detail |
| In 3T3 fibroblasts expressing the L239R mutation h... | DDR2 |
DDR2 p.Leu239Arg (p.L239R) ( ENST00000367922.7, ENST00000446985.6, ENST00000367921.8 ) DDR2 p.Leu239Arg (p.L239R) ( ENST00000367921.8, ENST00000367922.7, ENST00000446985.6 ) |
Sensitivity | true | CIViC Evidence | detail |
| In 3T3 fibroblasts expressing the L63V mutation ha... | DDR2 |
DDR2 p.Leu63Val (p.L63V) ( ENST00000367921.8, ENST00000367922.7, ENST00000446985.6 ) DDR2 p.Leu63Val (p.L63V) ( ENST00000367922.7, ENST00000367921.8, ENST00000446985.6 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a patient expressing a DDR2 S768R mutation, tre... | DDR2 |
DDR2 p.Ser768Arg (p.S768R) ( ENST00000367921.8, ENST00000367922.7, ENST00000446985.6 ) DDR2 p.Ser768Arg (p.S768R) ( ENST00000367921.8, ENST00000446985.6, ENST00000367922.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| High-throughput drug screens in OCCC tumor cell m... | ARID1A | ARID1A MUTATION ARID1A MUTATION | Sensitivity | true | CIViC Evidence | detail |
| KIT(V559D) were expressed in HEK-293 cells (in vit... | KIT |
KIT p.Val560Asp (p.V560D) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val560Asp (p.V560D) ( ENST00000690543.1, ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000692783.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| Ba/F3 cells harboring the KIT L576P mutation are s... | KIT |
KIT p.Leu577Pro (p.L577P) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Leu577Pro (p.L577P) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| In this phase II multinational study, patients wit... | ABL1 |
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) |
N/A | true | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Prior to dasatinib treatment, two imatinib-resista... | ABL1 |
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, COS-7 cells expressing KIT L... | KIT |
KIT p.Leu577Pro (p.L577P) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Leu577Pro (p.L577P) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a phase 2 clinical trial of 39 stage 3/4 chemot... | KIT |
KIT p.Lys643Glu (p.K643E) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys643Glu (p.K643E) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| The melanoma cell line WM3211, which harbors the L... | KIT |
KIT p.Leu577Pro (p.L577P) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Leu577Pro (p.L577P) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this phase II multinational study, 60 imatinib-... | ABL1 |
ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this phase II multinational study, patients wit... | ABL1 |
ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) |
N/A | true | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Gln271His (p.Q271H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gln271His (p.Q271H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this phase II multinational study, 60 imatinib-... | ABL1 |
ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this phase II multinational study, patients wit... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | N/A | true | CIViC Evidence | detail |
| Prior to dasatinib treatment, one imatinib-resista... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Asp295Gly (p.D295G) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Asp295Gly (p.D295G) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this phase II multinational study, patients wit... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this phase II multinational study, patients wit... | ABL1 |
ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) |
N/A | true | CIViC Evidence | detail |
| In this phase II multinational study, patients wit... | ABL1 |
ABL1 p.Glu374Gly (p.E374G) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu374Gly (p.E374G) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Glu374Gly (p.E374G) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu374Gly (p.E374G) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Prior to dasatinib treatment, three imatinib-resis... | ABL1 |
ABL1 p.Glu374Gly (p.E374G) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu374Gly (p.E374G) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Leu406Met (p.L406M) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu406Met (p.L406M) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Prior to dasatinib treatment, one imatinib-resista... | ABL1 |
ABL1 p.Leu406Met (p.L406M) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu406Met (p.L406M) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Prior to dasatinib treatment, one imatinib-resista... | ABL1 | ABL1 BCR-ABL | Sensitivity | true | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Three chronic myeloid leukemia patients had the BC... | ABL1 |
ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this phase II multinational study, patients wit... | ABL1 |
ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Prior to dasatinib treatment, one imatinib-resista... | ABL1 |
ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In an in vitro study, a HCT116 cell line expressin... | ARID1A |
ARID1A p.Gln456Ter (p.Q456*) ( ENST00000324856.13, ENST00000374152.7, ENST00000430799.7, ENST00000457599.7 ) ARID1A p.Gln456Ter (p.Q456*) ( ENST00000324856.13, ENST00000457599.7, ENST00000374152.7, ENST00000430799.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Leu403Met (p.L403M) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu403Met (p.L403M) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Prior to dasatinib treatment, one imatinib-resista... | ABL1 |
ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Glu298Lys (p.E298K) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu298Lys (p.E298K) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line stably ex... | ABL1 | ABL1 p.Gly417Arg (p.G417R) ABL1 p.Gly417Arg (p.G417R) | Sensitivity | true | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 | ABL1 p.Phe505Ser (p.F505S) ABL1 p.Phe505Ser (p.F505S) | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Prior to dasatinib treatment, one imatinib-resista... | ABL1 | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this phase II multinational study, patients wit... | ABL1 |
ABL1 p.Val398Ile (p.V398I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Val398Ile (p.V398I) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Prior to dasatanib treatment, fifteen imatinib-res... | ABL1 | ABL1 BCR-ABL | Sensitivity | true | CIViC Evidence | detail |
| In this phase II multinational study, patients wit... | ABL1 | ABL1 p.Ala416Pro (p.A416P) ABL1 p.Ala416Pro (p.A416P) | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Prior to dasatinib treatment, one imatinib-resista... | ABL1 | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Prior to dasatinib treatment, one imatinib-resista... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this in vitro study, the H1915 non-small cell l... | ABL1 |
ABL1 p.Arg351Trp (p.R351W) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Arg351Trp (p.R351W) ( ENST00000318560.6, ENST00000372348.9 ) |
Sensitivity | true | CIViC Evidence | detail |
| In this in vitro study, the H2110 non-small cell l... | ABL1 |
ABL1 p.Gly340Leu (p.G340L) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gly340Leu (p.G340L) ( ENST00000318560.6, ENST00000372348.9 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, COS-7 cells expressing KIT S... | KIT |
KIT p.Ser629Asn (p.S629N) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Ser629Asn (p.S629N) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a HCH1 cell line expressing ... | ARID1A | ARID1A P1175FS*5 ARID1A P1175FS*5 | Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 |
ABL1 p.Thr334Ala (p.T334A) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Thr334Ala (p.T334A) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 |
ABL1 p.Phe336Val (p.F336V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe336Val (p.F336V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 |
ABL1 p.Leu267Arg (p.L267R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu267Arg (p.L267R) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 | ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 |
ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 |
ABL1 p.Phe336Ile (p.F336I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe336Ile (p.F336I) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 |
ABL1 p.Phe336Ser (p.F336S) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe336Ser (p.F336S) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 |
ABL1 p.Gln271His (p.Q271H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gln271His (p.Q271H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Phe336Cys (p.F336C) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe336Cys (p.F336C) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Phe336Ile (p.F336I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe336Ile (p.F336I) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Phe336Val (p.F336V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe336Val (p.F336V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 | ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Gln271His (p.Q271H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gln271His (p.Q271H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 | ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 |
ABL1 p.Glu478Lys (p.E478K) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu478Lys (p.E478K) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This is a retrospective study of imatinib-resistan... | ABL1 | ABL1 MUTATION ABL1 MUTATION | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| BCR-ABL F317L has been shown to confer resistance ... | ABL1 | ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Through a high-throughput drug screen of a large p... | IDH1 | IDH1 R132 IDH1 R132 | Sensitivity | true | CIViC Evidence | detail |
| An adult patient (82 yo) who presented with B-ALL ... | ABL1 | ABL1 ETV6-ABL1 | Sensitivity | true | CIViC Evidence | detail |
| In this phase II multinational study, 60 imatinib-... | ABL1 |
ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In this phase II multinational study, patients wit... | ABL1 | ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) | N/A | true | CIViC Evidence | detail |
| In this phase II multinational study, patients wit... | ABL1 |
ABL1 p.Glu478Lys (p.E478K) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu478Lys (p.E478K) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| The EBF1-PDGFRB fusion was detected in leukemia ce... | PDGFRB | PDGFRB EBF1-PDGFRB | Sensitivity | true | CIViC Evidence | detail |
| A 7-yr-old boy with B-cell precursor acute lymphob... | ABL1 | ABL1 SNX2-ABL1 Fusion | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| The ABL1-RCSD1 fusion was identified in a 6 yo boy... | ABL1 | ABL1 ABL1-RCSD1 | Sensitivity | true | CIViC Evidence | detail |
| The ABL2-RCSD1 fusion was identified in a 5 yo boy... | ABL2 | ABL2 ABL2 fusions ABL2 ABL2 fusions | Sensitivity | true | CIViC Evidence | detail |
| A 16-year-old Caucasian boy was diagnosed with B-A... | ABL1 | ABL1 FOXP1-ABL1 Fusion | Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, COS-7 cells expressing KIT D... | KIT |
KIT p.Asp817Val (p.D817V) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asp817Val (p.D817V) ( ENST00000686011.1, ENST00000687109.1, ENST00000288135.6, ENST00000412167.7, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| SNX2-ABL1 protein (SNX2 exon 3 to ABL1 exon 4) was... | ABL1 | ABL1 SNX2-ABL1 Fusion | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Bone marrow mononuclear cells (BM MNCs) isolated f... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Bone marrow mononuclear cells (BM MNCs) were isola... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Bone marrow mononuclear cells isolated from a chro... | ABL1 | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | Sensitivity | true | CIViC Evidence | detail |
| Prior to dasatinib treatment, one imatinib-resista... | ABL1 |
ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Prior to dasatinib treatment, one imatinib-resista... | ABL1 | ABL1 BCR-ABL F311V ABL1 BCR-ABL F311V | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Prior to dasatinib treatment, one imatinib-resista... | ABL1 |
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Combined treatment with dasatinib and cetuximab, b... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Dasatinib is a SRC inhibitor | SRC | SRC EXPRESSION | Sensitivity | true | MMMP | detail |
| Dasatinib (a dual Src/Abl inhibitor) blocks migrat... | SRC | SRC EXPRESSION | Sensitivity | true | MMMP | detail |
| Dasatinib inhibited growth of three of the five me... | SRC | SRC EXPRESSION | Sensitivity | true | MMMP | detail |
| Mucosal melanoma. Two metastatic melanoma patients... | KIT | KIT L576P | Sensitivity | true | MMMP | detail |
| The mutant melanoma cell line was sensitive to das... | KIT | KIT L576P | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03117751 | Active, not recruiting | Phase 2/Phase 3 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | March 29, 2017 | March 31, 2028 |
| NCT04147533 | Active, not recruiting | Phase 2 | Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia | June 16, 2020 | June 2026 |
| NCT04164069 | Active, not recruiting | Phase 1 | Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab | September 2, 2020 | December 31, 2023 |
| NCT05192889 | Active, not recruiting | Phase 1/Phase 2 | Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | August 25, 2022 | July 2029 |
| NCT00254423 | Active, not recruiting | Phase 2 | Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia | November 8, 2005 | November 30, 2024 |
| NCT00777036 | Active, not recruiting | Phase 2 | A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib | March 20, 2009 | December 7, 2029 |
| NCT02883049 | Active, not recruiting | Phase 3 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | February 29, 2012 | September 22, 2024 |
| NCT02689440 | Active, not recruiting | Phase 2 | Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia | February 19, 2016 | December 31, 2040 |
| NCT02494882 | Active, not recruiting | Phase 1 | Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older | June 29, 2015 | June 2025 |
| NCT00792948 | Active, not recruiting | Phase 2 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia | September 1, 2009 | January 6, 2025 |
| NCT03020030 | Active, not recruiting | Phase 3 | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | March 3, 2017 | November 2034 |
| NCT02465060 | Active, not recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | August 17, 2015 | December 31, 2025 |
| NCT04578847 | Active, not recruiting | Phase 2 | A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) | January 15, 2020 | January 15, 2025 |
| NCT02389309 | Active, not recruiting | Phase 1 | Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors | October 5, 2015 | October 31, 2024 |
| NCT04329325 | Active, not recruiting | Phase 2 | Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | March 30, 2020 | March 2025 |
| NCT03906292 | Active, not recruiting | Phase 2 | Frontline Asciminib Combination in Chronic Phase CML | August 19, 2019 | December 2027 |
| NCT02143414 | Active, not recruiting | Phase 2 | Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia | June 30, 2015 | October 23, 2024 |
| NCT03654768 | Active, not recruiting | Phase 2 | Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia | October 24, 2018 | July 1, 2028 |
| NCT01990196 | Active, not recruiting | Phase 2 | Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer | September 23, 2014 | September 30, 2025 |
| NCT04971226 | Active, not recruiting | Phase 3 | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | October 6, 2021 | January 18, 2028 |
| NCT00070499 | Active, not recruiting | Phase 2 | Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia | August 15, 2004 | February 22, 2025 |
| NCT01660971 | Active, not recruiting | Phase 1 | Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | July 30, 2012 | March 7, 2025 |
| NCT01471106 | Active, not recruiting | Phase 2 | Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer | January 21, 2014 | January 31, 2025 |
| NCT03193281 | Active, not recruiting | Phase 2 | KISS Study: Kinase Inhibition With Sprycel Start up | July 17, 2017 | December 31, 2025 |
| NCT04313634 | Active, not recruiting | Phase 2 | Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans | June 9, 2020 | June 6, 2024 |
| NCT00429234 | Completed | Phase 1 | Gemcitabine and Dasatinib in Advanced Solid Tumors | January 2007 | February 2013 |
| NCT00429949 | Completed | Phase 2 | A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma | January 2007 | January 2008 |
| NCT00436605 | Completed | Phase 2 | Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma | December 2006 | November 2010 |
| NCT00438854 | Completed | Phase 2 | Dasatinib in Relapsed Chronic Lymphocytic Leukemia | December 2006 | March 2013 |
| NCT00439270 | Completed | Phase 1/Phase 2 | Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer | July 2007 | January 2013 |
| NCT00452673 | Completed | Phase 1 | Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer | June 2007 | October 2012 |
| NCT00459342 | Completed | Phase 2 | Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | March 2007 | April 2012 |
| NCT00464620 | Completed | Phase 2 | Trial of Dasatinib in Advanced Sarcomas | May 2007 | May 2017 |
| NCT00470054 | Completed | Phase 2 | Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer | April 2007 | April 2013 |
| NCT00474812 | Completed | Phase 2 | Dasatinib in Treating Patients With Metastatic Pancreatic Cancer | May 2007 | February 2014 |
| NCT00481247 | Completed | Phase 3 | A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia | September 2007 | December 2015 |
| NCT00482703 | Completed | Phase 1/Phase 2 | A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia | May 2007 | May 2009 |
| NCT00495872 | Completed | Phase 1 | Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor | June 2007 | |
| NCT00501410 | Completed | Phase 1 | FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer | April 23, 2007 | March 3, 2017 |
| NCT00504153 | Completed | Phase 2 | Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer | July 2007 | June 2011 |
| NCT00507767 | Completed | Phase 2 | Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | July 2007 | February 2010 |
| NCT00509041 | Completed | Phase 2 | Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma | August 2007 | December 2012 |
| NCT00529763 | Completed | Phase 2 | Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects | November 17, 2007 | April 20, 2022 |
| NCT00546104 | Completed | Phase 2 | Phase II Dasatinib Study in Advanced Breast Cancer | October 2007 | May 2011 |
| NCT00550615 | Completed | Phase 1/Phase 2 | Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma | September 17, 2007 | December 1, 2017 |
| NCT00563290 | Completed | Phase 2 | Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia | November 2007 | October 2014 |
| NCT00566618 | Completed | Phase 1/Phase 2 | Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis | November 1, 2007 | November 17, 2020 |
| NCT00568750 | Completed | Phase 2 | Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors | January 22, 2008 | May 16, 2018 |
| NCT00570401 | Completed | Phase 2 | Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib | June 2006 | September 2011 |
| NCT00570700 | Completed | Phase 2 | Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer | July 2007 | February 2012 |
| NCT00608361 | Completed | Phase 1 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | October 2008 | August 2014 |
| NCT00624585 | Completed | N/A | Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts | February 2008 | May 2012 |
| NCT00036738 | Completed | Phase 2 | Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib | July 13, 2001 | May 2018 |
| NCT00662636 | Completed | Phase 1 | Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery | August 2008 | December 18, 2014 |
| NCT00671788 | Completed | Phase 2 | A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | June 2008 | |
| NCT00696072 | Completed | Phase 2 | Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic | August 2008 | June 2014 |
| NCT00700882 | Completed | Phase 2 | Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery | July 2, 2009 | December 28, 2020 |
| NCT00706641 | Completed | N/A | Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder | June 2008 | December 2012 |
| NCT00717704 | Completed | Phase 1 | Solid Tumors Using Ixabepilone and Dasatinib | July 2008 | May 2011 |
| NCT00720109 | Completed | Phase 2/Phase 3 | Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | July 14, 2008 | March 31, 2020 |
| NCT00744497 | Completed | Phase 3 | Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer | October 2008 | July 2015 |
| NCT00754325 | Completed | Phase 2 | Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor | September 2008 | January 2014 |
| NCT00764309 | Completed | Phase 1/Phase 2 | Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis | January 2009 | April 2011 |
| NCT00816283 | Completed | Phase 1 | Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia | September 2008 | June 2011 |
| NCT00826449 | Completed | Phase 1/Phase 2 | Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC) | February 2009 | June 2014 |
| NCT00850382 | Completed | Phase 1/Phase 2 | Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) | June 2009 | November 2015 |
| NCT00852566 | Completed | Phase 2 | Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia | March 2009 | December 2015 |
| NCT00859937 | Completed | Phase 2 | Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors | March 16, 2009 | |
| NCT00866736 | Completed | Phase 2 | A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia | March 2009 | June 2012 |
| NCT00869401 | Completed | Phase 1/Phase 2 | Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | June 2009 | November 15, 2019 |
| NCT00892177 | Completed | Phase 2 | Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme | October 2009 | July 1, 2019 |
| NCT00895128 | Completed | Phase 1 | Study of Erlotinib in Combination With Dasatinib | April 2009 | |
| NCT00652574 | Completed | Phase 1 | Dasatinib in Resectable Malignant Pleural Mesothelioma | March 12, 2008 | October 7, 2022 |
| NCT00064233 | Completed | Phase 1 | BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate | November 2003 | October 2006 |
| NCT00099606 | Completed | Phase 1 | Phase I (PH I) Mad Refractory Solid Tumor Study | July 2004 | July 2007 |
| NCT00101595 | Completed | Phase 2 | Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | January 2005 | December 2007 |
| NCT00101647 | Completed | Phase 2 | Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia | December 2004 | March 2008 |
| NCT00101660 | Completed | Phase 2 | Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib | February 2005 | April 2008 |
| NCT00101816 | Completed | Phase 2 | Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate | December 2004 | March 2008 |
| NCT00103701 | Completed | Phase 1 | BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia | November 2003 | March 2006 |
| NCT00103844 | Completed | Phase 2 | Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia | February 2005 | March 2008 |
| NCT00123474 | Completed | Phase 3 | Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML | July 2005 | July 2014 |
| NCT00123487 | Completed | Phase 3 | Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML | June 2005 | June 2013 |
| NCT00298987 | Completed | Phase 2 | A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate | February 2006 | June 2007 |
| NCT00306202 | Completed | Phase 1 | Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia | March 31, 2006 | May 22, 2019 |
| NCT00316953 | Completed | Phase 1 | Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate | March 2006 | |
| NCT00337454 | Completed | Phase 1/Phase 2 | Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan | July 2005 | March 2007 |
| NCT00339144 | Completed | Phase 1 | Study of Dasatinib (BMS-354825) in Patients With Solid Tumors | January 2007 | September 2008 |
| NCT00345826 | Completed | Phase 1 | Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia | November 2005 | |
| NCT00371254 | Completed | Phase 2 | A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer | December 2006 | September 2008 |
| NCT00371345 | Completed | Phase 2 | Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer | December 2006 | May 2009 |
| NCT00382668 | Completed | A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug | October 2006 | August 2007 | |
| NCT00385580 | Completed | Phase 2 | Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer | January 2007 | October 2010 |
| NCT00390793 | Completed | Phase 2 | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | September 28, 2006 | February 2, 2024 |
| NCT00391989 | Completed | Phase 2 | Treatment of Adult Ph+ LAL With BMS-354825 | September 2006 | September 2008 |
| NCT00410813 | Completed | Phase 2 | S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone | March 2007 | January 2014 |
| NCT00423735 | Completed | Phase 2 | Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | January 24, 2007 | September 4, 2018 |
| NCT00920868 | Completed | Phase 1 | XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | May 2009 | August 2014 |
| NCT00924352 | Completed | Phase 1/Phase 2 | Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer | June 2009 | October 2013 |
| NCT00978731 | Completed | Phase 1 | Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study | December 2005 | September 2008 |
| NCT00982488 | Completed | Phase 2 | Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | October 2007 | December 2014 |
| NCT01004497 | Completed | Phase 2 | First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL | March 2010 | April 2015 |
| NCT01015222 | Completed | Phase 1 | Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies | November 2009 | May 27, 2021 |
| NCT01030718 | Completed | Phase 1/Phase 2 | Rollover Study of BMS-354825 in Patients With CML and Ph+ALL | January 2006 | June 2009 |
| NCT01218477 | Completed | Phase 1/Phase 2 | Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) | January 2011 | April 2013 |
| NCT01234935 | Completed | Phase 2 | Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery | January 13, 2011 | November 27, 2017 |
| NCT01238211 | Completed | Phase 2 | Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | December 14, 2010 | March 15, 2021 |
| NCT01254864 | Completed | Phase 2 | Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies | March 16, 2011 | December 7, 2023 |
| NCT01256398 | Completed | Phase 2 | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | December 14, 2010 | November 15, 2021 |
| NCT01260688 | Completed | Phase 2 | Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel | October 2010 | February 2014 |
| NCT01306942 | Completed | Phase 1/Phase 2 | Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | July 2011 | March 15, 2019 |
| NCT01310010 | Completed | Phase 2 | Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia | April 2010 | July 2016 |
| NCT01342679 | Completed | Phase 2 | A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib | April 2011 | September 2014 |
| NCT01395017 | Completed | Phase 2 | Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer | June 2011 | March 2015 |
| NCT01398046 | Completed | Phase 1 | Effects of Gastric pH on the Pharmacokinetics of Dasatinib | August 2011 | February 2014 |
| NCT01440998 | Completed | Phase 1 | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | September 20, 2011 | December 31, 2015 |
| NCT01441882 | Completed | Phase 2 | Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia | October 2011 | January 1, 2018 |
| NCT01445509 | Completed | Phase 1 | Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors | December 29, 2008 | September 20, 2018 |
| NCT01460160 | Completed | Phase 2 | Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia | April 13, 2012 | June 1, 2021 |
| NCT01460693 | Completed | Phase 3 | Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia | August 2008 | March 7, 2018 |
| NCT01467986 | Completed | Phase 2 | Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma | August 2013 | September 30, 2020 |
| NCT01482728 | Completed | Early Phase 1 | Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer | January 2012 | December 2015 |
| NCT01593254 | Completed | Phase 2 | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib | September 12, 2012 | April 12, 2022 |
| NCT01636908 | Completed | N/A | Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. | August 2011 | December 1, 2019 |
| NCT01643278 | Completed | Phase 1 | Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic | July 2012 | June 2016 |
| NCT01644773 | Completed | Phase 1 | Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) | November 27, 2012 | September 28, 2018 |
| NCT01652976 | Completed | Phase 2 | Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma | July 2012 | July 2020 |
| NCT01660906 | Completed | Phase 4 | Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib | December 2012 | October 2015 |
| NCT01724879 | Completed | Phase 2 | Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL) | November 2011 | September 2015 |
| NCT01744652 | Completed | Phase 1 | Dasatinib and Crizotinib in Advanced Cancer | March 2013 | March 2019 |
| NCT01850004 | Completed | Phase 2 | Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response | January 22, 2014 | October 8, 2021 |
| NCT01872442 | Completed | Phase 2 | Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase | October 15, 2013 | October 31, 2018 |
| NCT01876212 | Completed | Phase 2 | Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma | May 16, 2014 | July 31, 2019 |
| NCT01916785 | Completed | Phase 2 | OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy) | May 2009 | December 2013 |
| NCT02011945 | Completed | Phase 1 | A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia | February 7, 2014 | December 26, 2018 |
| NCT02013648 | Completed | Phase 3 | Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) | July 2014 | February 2024 |
| NCT02081378 | Completed | Phase 1 | A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL | April 24, 2014 | March 14, 2023 |
| NCT02113319 | Completed | Phase 2 | Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia | April 2007 | |
| NCT02297139 | Completed | Phase 2 | Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib | July 31, 2015 | May 15, 2022 |
| NCT02389972 | Completed | Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study | April 11, 2013 | July 13, 2017 | |
| NCT02428855 | Completed | Phase 2 | Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma | April 2015 | February 2018 |
| NCT02523976 | Completed | Phase 2 | Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | August 1, 2015 | December 31, 2021 |
| NCT02546791 | Completed | Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study | July 22, 2015 | March 29, 2017 | |
| NCT02596828 | Completed | Phase 2 | Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma | April 2016 | April 2021 |
| NCT02733445 | Completed | Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib | December 2015 | March 2016 | |
| NCT02779283 | Completed | Phase 1 | Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia | January 13, 2016 | September 20, 2018 |
| NCT02888990 | Completed | Phase 2 | Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia | August 2007 | January 2016 |
| NCT03023046 | Completed | Phase 2 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | February 23, 2017 | May 1, 2022 |
| NCT03625388 | Completed | Phase 2 | Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia | November 5, 2018 | July 22, 2023 |
| NCT03885830 | Completed | Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients | June 20, 2019 | June 15, 2022 | |
| NCT04580121 | Completed | Phase 1 | A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. | November 4, 2020 | August 9, 2023 |
| NCT05286528 | Completed | Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database | November 18, 2020 | January 31, 2022 | |
| NCT05422885 | Completed | Phase 1/Phase 2 | Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease | May 20, 2022 | January 24, 2024 |
| NCT04785300 | Enrolling by invitation | Phase 1/Phase 2 | ALSENLITE: Senolytics for Alzheimer's Disease | July 6, 2022 | December 2024 |
| NCT00454753 | No longer available | Expanded Access for Dasatinib | |||
| NCT05751044 | Not yet recruiting | Phase 1/Phase 2 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | October 1, 2023 | October 1, 2030 |
| NCT06124157 | Not yet recruiting | Phase 3 | A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) | July 22, 2024 | December 1, 2030 |
| NCT06055621 | Not yet recruiting | Phase 2 | Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE | December 31, 2023 | October 31, 2025 |
| NCT06390319 | Not yet recruiting | Phase 2 | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | June 2024 | December 2033 |
| NCT06355037 | Not yet recruiting | Phase 2 | Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer | April 10, 2024 | January 31, 2025 |
| NCT05725200 | Recruiting | Phase 2 | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | September 27, 2022 | December 31, 2040 |
| NCT05007873 | Recruiting | Phase 2 | ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase | October 21, 2021 | October 30, 2024 |
| NCT04530565 | Recruiting | Phase 3 | Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults | January 25, 2021 | July 1, 2028 |
| NCT05559008 | Recruiting | Phase 1/Phase 2 | A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | September 30, 2022 | January 26, 2026 |
| NCT04872790 | Recruiting | Phase 1 | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia | September 2, 2022 | June 2, 2026 |
| NCT04877522 | Recruiting | Phase 4 | Asciminib Roll-over Study | August 30, 2022 | August 30, 2027 |
| NCT04925648 | Recruiting | Phase 2 | Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction | October 18, 2021 | June 1, 2025 |
| NCT03595917 | Recruiting | Phase 1 | ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML | July 24, 2018 | November 1, 2026 |
| NCT03516279 | Recruiting | Phase 2 | Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease | June 26, 2019 | August 31, 2031 |
| NCT03297606 | Recruiting | Phase 2 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | March 23, 2018 | January 31, 2027 |
| NCT02326311 | Recruiting | Phase 3 | Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response | June 10, 2015 | December 31, 2023 |
| NCT04838041 | Recruiting | Phase 2 | Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation | November 11, 2021 | July 2029 |
| NCT04747912 | Recruiting | Phase 2 | Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) | March 2, 2021 | May 1, 2026 |
| NCT03173612 | Recruiting | N/A | The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia | August 2016 | December 2024 |
| NCT06336395 | Recruiting | Phase 2 | Ma-Spore ALL 2020 Study | March 4, 2020 | March 2030 |
| NCT04835584 | Recruiting | Phase 1/Phase 2 | KRT-232 and TKI Study in Chronic Myeloid Leukemia | May 7, 2021 | June 30, 2026 |
| NCT05432518 | Recruiting | Early Phase 1 | Pilot Trial for Treatment of Recurrent Glioblastoma | June 27, 2023 | December 1, 2027 |
| NCT02559778 | Recruiting | Phase 2 | Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | September 2015 | September 2035 |
| NCT05527418 | Recruiting | Phase 2 | Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection | January 26, 2024 | June 2026 |
| NCT05993949 | Recruiting | Phase 1 | Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia | October 2, 2023 | August 2025 |
| NCT05198843 | Terminated | Phase 1/Phase 2 | Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body | November 8, 2022 | December 20, 2023 |
| NCT01751425 | Terminated | Phase 1 | Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors | July 24, 2013 | September 24, 2019 |
| NCT01876953 | Terminated | Phase 1/Phase 2 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | September 13, 2013 | April 25, 2018 |
| NCT00860158 | Terminated | Phase 2 | Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer | March 2009 | December 2010 |
| NCT00320190 | Terminated | Phase 2 | Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib | August 2006 | January 2010 |
| NCT02043587 | Terminated | Phase 2 | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | January 2014 | April 14, 2022 |
| NCT02059265 | Terminated | Phase 2 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | February 14, 2014 | June 26, 2023 |
| NCT00858403 | Terminated | Phase 2 | Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation | March 2009 | July 2010 |
| NCT00835679 | Terminated | Early Phase 1 | Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery | December 2009 | August 2011 |
| NCT02420717 | Terminated | Phase 2 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | July 15, 2015 | January 20, 2021 |
| NCT00817531 | Terminated | Phase 2 | Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients | December 2008 | February 2011 |
| NCT00788125 | Terminated | Phase 1/Phase 2 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | September 3, 2008 | July 30, 2022 |
| NCT00787267 | Terminated | Phase 2 | Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC | September 2008 | June 2013 |
| NCT02709083 | Terminated | Phase 2 | Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia | October 2016 | July 2018 |
| NCT02720185 | Terminated | Phase 2 | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR | May 3, 2017 | February 8, 2022 |
| NCT02750514 | Terminated | Phase 2 | An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer | May 9, 2016 | January 29, 2020 |
| NCT02819804 | Terminated | Phase 1 | Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | August 17, 2017 | August 30, 2018 |
| NCT00780676 | Terminated | Phase 2 | Personalized Treatment Selection for Metastatic Breast Cancer | June 2009 | May 2014 |
| NCT00598091 | Terminated | Phase 1 | A Phase I/Expansion Study of Dasatinib | April 2007 | May 2012 |
| NCT03041701 | Terminated | Phase 1/Phase 2 | Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | July 7, 2017 | October 16, 2021 |
| NCT00895960 | Terminated | Phase 1 | Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma | May 7, 2009 | August 2013 |
| NCT00903006 | Terminated | Phase 1/Phase 2 | Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer | November 2009 | May 2013 |
| NCT00918385 | Terminated | Phase 2 | Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer | May 2009 | August 2013 |
| NCT00918463 | Terminated | Phase 2 | A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | June 2009 | May 23, 2011 |
| NCT00564876 | Terminated | Phase 2 | Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer | November 2007 | September 2009 |
| NCT00948389 | Terminated | Phase 1/Phase 2 | Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) | October 2009 | May 2011 |
| NCT00560352 | Terminated | Phase 1 | Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma | February 2008 | February 2011 |
| NCT03352427 | Terminated | Phase 2 | Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations | December 6, 2017 | May 15, 2019 |
| NCT03515200 | Terminated | Phase 1 | Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia | April 20, 2018 | July 29, 2020 |
| NCT01092728 | Terminated | Phase 2 | Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma | March 2011 | August 2014 |
| NCT01116128 | Terminated | Phase 2 | Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients | February 2008 | May 2011 |
| NCT01173679 | Terminated | Phase 2 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | July 2010 | January 2015 |
| NCT00544908 | Terminated | Phase 2 | Dasatinib in Treating Patients With Stage IV Pancreatic Cancer | September 2007 | |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT01357655 | Terminated | Phase 2 | Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) | September 2011 | January 2016 |
| NCT00538980 | Terminated | Phase 2 | Dasatinib in Polycythemia Vera | April 30, 2007 | August 27, 2010 |
| NCT01426334 | Terminated | Phase 1 | Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate | September 2011 | |
| NCT04115059 | Terminated | Phase 1 | Dasatinib In Waldenström Macroglobulinemia | November 4, 2019 | December 31, 2021 |
| NCT00500006 | Terminated | Phase 1 | A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) | October 2007 | November 2007 |
| NCT00459108 | Terminated | Phase 2 | Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery | April 2007 | April 2011 |
| NCT00362466 | Terminated | Phase 3 | A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy | April 2007 | June 2008 |
| NCT00882583 | Terminated | Phase 1 | A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC | July 2009 | February 2016 |
| NCT01488318 | Terminated | Phase 2 | Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma | September 2011 | August 2016 |
| NCT01491633 | Terminated | Phase 2 | Dasatinib in Advanced Squamous Cell Lung Cancer | September 2011 | May 2013 |
| NCT01498445 | Terminated | Phase 1/Phase 2 | An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) | June 12, 2012 | September 24, 2019 |
| NCT01514864 | Terminated | Phase 2 | Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation | May 31, 2012 | July 23, 2014 |
| NCT01609816 | Terminated | Phase 1 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma | February 12, 2015 | October 9, 2018 |
| NCT01620216 | Terminated | Phase 2 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | May 11, 2012 | April 30, 2017 |
| NCT01643603 | Terminated | Phase 1 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies | May 2012 | October 9, 2018 |
| NCT03573596 | Unknown status | Phase 2 | Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment | February 1, 2018 | February 1, 2024 |
| NCT02744768 | Unknown status | Phase 2 | D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia | May 31, 2017 | June 2021 |
| NCT02015728 | Unknown status | N/A | Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors | December 2013 | December 2017 |
| NCT01685125 | Unknown status | Phase 2 | Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | September 2012 | March 2018 |
| NCT04155411 | Unknown status | Phase 4 | Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP | December 1, 2019 | December 1, 2023 |
| NCT00979160 | Unknown status | Phase 2 | Evaluation of Response of Dasatinib to Treat Mastocytosis | November 2009 | December 2012 |
| NCT00112775 | Unknown status | Phase 2 | BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate | March 2005 | |
| NCT01627132 | Unknown status | Phase 2 | Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial | February 2012 | January 2019 |
| NCT05024357 | Unknown status | N/A | A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL | September 6, 2021 | June 30, 2023 |
| NCT01051115 | Unknown status | Phase 2 | Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease | October 2008 | January 2016 |
| NCT04933526 | Unknown status | Phase 4 | The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients | July 1, 2021 | June 30, 2023 |
| NCT02268370 | Unknown status | Phase 2 | Treatment-free Remission Accomplished With Dasatinib in Patients With CML | October 2014 | October 2021 |
| NCT03564470 | Unknown status | Phase 2/Phase 3 | Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL | February 14, 2016 | August 30, 2023 |
| NCT02233049 | Unknown status | Phase 2 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication | October 2014 | October 2018 |
| NCT02776878 | Unknown status | N/A | A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST | May 2016 | May 2018 |
| NCT02690922 | Unknown status | Phase 4 | Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients | March 2016 | May 2017 |
| NCT01802450 | Unknown status | Phase 2 | Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase | March 2013 | December 2016 |
| NCT03844360 | Unknown status | Phase 4 | Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease | January 31, 2016 | December 31, 2021 |
| NCT02954523 | Unknown status | Phase 1/Phase 2 | Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | October 2016 | June 2023 |
| NCT01887561 | Unknown status | Phase 2 | Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial | November 2012 | |
| NCT02638428 | Unknown status | Phase 2 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | December 2015 | December 2023 |
| NCT05042531 | Unknown status | N/A | Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia | November 13, 2021 | December 15, 2023 |
| NCT01804985 | Unknown status | Phase 2 | De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia | December 2013 | May 2018 |
| NCT02129166 | Withdrawn | Phase 1 | Explore the Synergy of Combination TKI Therapy | September 2014 | October 2014 |
| NCT03414450 | Withdrawn | Phase 1 | Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies | April 25, 2018 | February 2023 |
| NCT03560908 | Withdrawn | Phase 1 | Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | July 1, 2018 | December 31, 2021 |
| NCT02815059 | Withdrawn | Phase 1 | Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone | September 28, 2016 | January 9, 2018 |
| NCT01410708 | Withdrawn | Phase 2 | TORI 104 Pre-Surgical Dasatinib | ||
| NCT04439305 | Withdrawn | Phase 2 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) | February 25, 2016 | |
| NCT02680951 | Withdrawn | Phase 1 | Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia | December 2015 | December 15, 2017 |
| NCT02923986 | Withdrawn | Phase 1/Phase 2 | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS | September 1, 2017 | May 27, 2020 |
| NCT00872976 | Withdrawn | Phase 1 | Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | May 2009 | December 2011 |
| NCT04845035 | Withdrawn | Phase 2 | Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | January 2024 | January 2029 |
| NCT00349518 | Withdrawn | Phase 2/Phase 3 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | December 2006 | |
| NCT01826838 | Withdrawn | Phase 1 | Study of Dasatinib, Androgen Deprivation Therapy and Radiation | January 2013 | April 2013 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Sprycel
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2006
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2009
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Bcr-Abl
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Src
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- CML
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- Ph+ALL